Palisade Bio, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- J. D. Finley
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5800 Armada Drive Denver CA United States of America 92008
- IPO Date
- Mar 30, 2007
- CIK
- 0001357459
- Website
- palisadebio.com
- Similar Companies
- Business
- Palisade Bio, Inc. (Nasdaq: PALI) Palisade Bio, Inc. is a clinical-stage biopharmaceutical company that develops and advances novel oral therapeutics targeting autoimmune, inflammatory and fibrotic diseases, with a focus on inflammatory bowel disease indications including moderate-to-severe ulcerative colitis and fibrostenotic Crohn's disease. The company's lead product candidate, PALI-2108, comprises a locally bioactivated PDE4 inhibitor prodrug designed for once-daily oral administration to achieve sustained localized activation, low systemic exposure and controlled release within the gastrointestinal tract; it has demonstrated 100% clinical response in a Phase 1b ulcerative colitis cohort with favorable tolerability, and advances toward a Phase 2 trial evaluating clinical remission, response and pharmacodynamic biomarkers over 12 weeks plus a maintenance extension, alongside planned fibrostenotic Crohn's disease studies. Palisade Bio leverages a proprietary prodrug platform via an exclusive worldwide license from Giiant Pharma, Inc. for precision delivery technology and related compounds including rights to GT-2108 and GT-1908; it maintains a research collaboration and license agreement with the Regents of the University of California, as well as a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Founded in 1996 and headquartered in Carlsbad, California, the company operates primarily in the United States with global intellectual property protections such as a recent patent allowance in China for PALI-2108 extending to 2045. Recent developments include the closing of an upsized $138 million public offering of common stock in October 2025 with full exercise of the over-allotment option to fund pipeline advancement and operations; an agreement in July 2025 for the exercise of existing warrants raising approximately $3.9 million in gross proceeds; and a significant 9.99% stake acquisition by Perceptive Advisors LLC reported in October 2025.
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease
Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating
Palisade Bio, Inc. (NASDAQ:PALI) Receives $13.25 Average Price Target from Analysts
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
Palisade Bio, Inc. (NASDAQ:PALI) Sees Large Increase in Short Interest
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board